Maker of drug for opioid treatment will pay $102.5M to settle antitrust case
Forty-two states negotiated a nationwide settlement for $102.5 million with the maker of Suboxone, Indivior Inc.
Forty-two states negotiated a nationwide settlement for $102.5 million with the maker of Suboxone, Indivior Inc.
A UVA Health study reveals the rate of suicide attempts by poisoning among children and adolescents increased 30 percent in 2021 from 2019.
Call data from all U.S. poison centers is uploaded to a national database to help identify substance abuse and poisoning trends.
A coalition of 21 states is calling on President Biden to designate Mexican drug cartels as foreign terrorist organizations under federal law.
Virginia Governor Glenn Youngkin is proposing $230 million in new funding for behavioral health in his upcoming budget.
In recognition of National Recovery Month, the U.S. Congress Joint Economic Committee released a new analysis that finds the opioid epidemic cost the United States a record of nearly $1.5 trillion in 2020.

Among Medicaid enrollees with opioid use disorder, having a follow-up visit seven days after an emergency department visit lowers their risk of fatal or nonfatal overdoses within six months.

Virginia localities and stakeholders have now agreed to the $26 billion settlement framework negotiated against opioid distributors and Johnson & Johnson.

The Opioid Abatement Authority has received the first funds secured through Attorney General Mark R. Herring’s ongoing work to hold accountable the drug manufacturers, distributors, and others that helped create and prolong the opioid crisis.

Virginia is expected to receive more than half a billion dollars from opioid distributors McKesson, AmerisourceBergen and Cardinal, and opioid manufacturer Johnson & Johnson.